SGN-PDL1V

SGN-PDL1V is an investigational antibody-drug conjugate (ADC) targeting programmed death ligand 1 (PD-L1), developed for the treatment of advanced solid tumors. The drug consists of a monoclonal antibody directed against PD-L1, a microtubule-disrupting cytotoxic payload (monomethyl auristatin E, MMAE), and a protease-cleavable linker that attaches MMAE to the antibody. Upon binding to PD-L1-expressing tumor cells, the ADC is internalized and enzymatically cleaved to release MMAE inside the cell. This results in inhibition of microtubule polymerization and direct cytotoxicity against tumor cells. Additional mechanisms include immunogenic cell death and potential bystander effects on neighboring tumor cells. SGN-PDL1V also retains checkpoint blockade activity by inhibiting PD-1/PD-L1 signaling. The drug was originally developed by Seagen and is now under development by Pfizer following its acquisition of Seagen. It is currently being evaluated in phase 1 clinical trials for multiple advanced solid tumors including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal cancer, melanoma, and ovarian cancer.

Other names

anti-PD-L1 antibody-drug conjugate SGN-PDL1Vanti-PD-L-1 antibody-drug conjugate SGN-PDL1Vanti-PD-L 1 antibody-drug conjugate SGN-PDL1V